Mupirocin for Staph Infections

Indications and Efficacy

Mupirocin demonstrates excellent activity against Staphylococcus aureus (including MRSA) and Streptococcus species, which are common causes of skin infections 1

For recurrent staph infections, applying mupirocin in the anterior nares twice daily for the first 5 days each month can reduce recurrences by approximately 50% 2

Apply a small amount of mupirocin 2% ointment directly to the affected area 1
Typical treatment duration is 5-10 days 1
For larger furuncles (boils) and carbuncles, incision and drainage is the primary treatment, with mupirocin potentially used as adjunctive therapy 2, 3

Mupirocin is not appropriate for extensive infections requiring systemic therapy 2
For larger furuncles and all carbuncles, incision and drainage is required, with systemic antibiotics indicated if extensive surrounding cellulitis or fever is present 2
Prolonged or indiscriminate use should be avoided to prevent development of resistance 1

For staph infections with systemic signs (fever, extensive cellulitis) 3
For deeper infections or those not responding to topical therapy within 5 days 3
For immunocompromised patients with significant infections 3
For severe or extensive infections, particularly those with SIRS (Systemic Inflammatory Response Syndrome) 3

For recurrent furunculosis, consider a decolonization regimen:
For particularly persistent recurrent furunculosis, clindamycin 150 mg daily for 3 months decreases subsequent infections by approximately 80% 2

The Infectious Diseases Society of America recommends mupirocin 2% ointment for minor skin infections, including impetigo in children, and secondarily infected skin lesions, such as infected eczema, ulcers, or lacerations 4
The European Society of Clinical Microbiology and Infectious Diseases suggests mupirocin for impetigo and other superficial primary skin infections in adults 5
The Infectious Diseases Society of America also recommends mupirocin for secondarily infected wounds and skin lesions in adults 4
The Infectious Diseases Society of America guidelines indicate that mupirocin may not be sufficient for deep soft tissue infections, complicated skin and soft tissue infections in hospitalized patients, and cutaneous abscesses, which require incision and drainage or systemic antibiotics 4
The Infectious Diseases Society of America suggests that mupirocin may be used as adjunctive therapy for cutaneous abscesses after incision and drainage, and for septic bursitis or other purulent collections where drainage is essential 4, 6

The Infectious Diseases Society of America recommends intranasal mupirocin for nasal carriage eradication, although one study showed limited efficacy for preventing subsequent skin infections 6

The American Academy of Pediatrics recommends mupirocin as adjunctive therapy for skin abscesses, with incision and drainage as the primary treatment 7
For outbreak control and prevention, intranasal mupirocin (twice daily for 5-7 days) effectively eradicates MRSA nasal carriage, as supported by the Anaesthesia journal 7, 8
In cardiac surgery patients, applying 2% mupirocin to each nostril combined with chlorhexidine mouthwash starting at least 48 hours before surgery for a total of 5-7 days significantly reduces postoperative MRSA infections, according to the Anaesthesia journal 8

High-level mupirocin resistance (MIC >512 µg/mL) has been identified in S. aureus and is associated with treatment failure, as reported in the Pediatrics journal 7

The most effective MRSA decolonization regimen combines multiple interventions, including intranasal mupirocin 2% twice daily for 5-7 days, daily chlorhexidine body washes, and twice-daily chlorhexidine mouthwash for oropharyngeal decontamination, as recommended by the Pediatrics and Anaesthesia journals 7, 8